Company / Cash & Equivalents
Bruker Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$298.8M
FY2025
5-year range
$183.4M / $1.1B
FY2021-FY2025
Trend
+62.9%
vs FY2024
Sector context
#67 of 152
Health Care
What the data says
At $299M, Bruker's cash & equivalents ranks #67 of 152 in the Health Care sector. Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $299M.
Based on SEC 10-K filings.
$299M in FY2025 with a 5-year CAGR of -15.2%.
Declined from $488M to $299M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -22.6%
- 5-Year CAGR
- -15.2%
- 10-Year CAGR
- -
Sector benchmark
#67 of 152 in Health CareTop 44% of 152This company $298.8M Sector average $1.2B
▼
-74.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -15.2%, indicating a declining trend.
- In FY2025, cash & equivalents increased 62.9% year-over-year.
- Ranks #67 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $298.8M | +62.9% |
| FY2024 | $183.4M | -62.4% |
| FY2023 | $488.3M | -24.4% |
| FY2022 | $645.5M | -39.6% |
| FY2021 | $1.1B | +56.7% |
| FY2020 | $681.8M | +0.5% |
| FY2019 | $678.3M | +110.4% |
| FY2018 | $322.4M | -0.8% |
| FY2017 | $325.0M | -5.1% |
| FY2016 | $342.4M | +28.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026